Approval date | FDA | EMA | AIFA |
---|---|---|---|
Adults with moderate to severe AD inadequately controlled | March 2017 | September 2017 | August 2018a |
Adolescents 12-17 years, with moderate to severe AD inadequately controlled | March 2019 | August 2019 | November 2020b |
Children 6-11 years, with moderate to severe AD inadequately controlled | May 2020 | October 2020 | January 2022c |